-+ 0.00%
-+ 0.00%
-+ 0.00%

Grace Therapeutics to present Phase 3 STRIVE-ON GTX-104 safety trial results at AAN 2026

PUBT·04/14/2026 12:06:09
Listen to the news
Grace Therapeutics to present Phase 3 STRIVE-ON GTX-104 safety trial results at AAN 2026
  • Grace Therapeutics disclosed acceptance of abstract on STRIVE-ON Phase 3 safety trial for GTx-104, an intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage.
  • Poster presentation is scheduled for April 21, 2026 at American Academy of Neurology annual meeting in Chicago.
  • Abstract highlights safety and tolerability findings, positioning GTx-104 against oral nimodipine in randomized trial setting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grace Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604140800PRIMZONEFULLFEED9687727) on April 14, 2026, and is solely responsible for the information contained therein.